Steven Kanner insider trades: Caribou Biosciences (CRBU) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Steven reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 21, 2025 | CRBU | ↓ Sell10b5-1 | 3,564 | $1.35 | $5K | Direct | Feb 21, 2025 (0d) |
| Aug 25, 2022 | CRBU | ↓ Sell | 43,248 | $11.22 | $485K | Direct | Aug 26, 2022 (1d) |
| Oct 12, 2021 | CRBU | ↑ Buy | 114,860 | $1.92 | $221K | Direct | Oct 13, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRBU insiders
Open-market trades in the last 12 months
About Steven Kanner's insider trades
Steven Kanner is Chief Scientific Officer at Caribou Biosciences (CRBU). Since Oct 12, 2021, Steven has reported 1 open-market purchase worth $221K and 2 sales worth $490K on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (1% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include option exercises (6 filings), grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRBU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.